These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 9063480)

  • 61. Chemotherapy for gynecologic malignancies.
    Vermorken JB; Hoekman K
    Curr Opin Oncol; 1995 Sep; 7(5):457-65. PubMed ID: 8541392
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Effects of urinastatin against nephrotoxicity of cisplatinum].
    Arakawa A; Kato N; Asai H; Yasui Y; Suzumori K; Suzumori K; Yagami Y
    Gan To Kagaku Ryoho; 1990 Nov; 17(11):2229-34. PubMed ID: 2241187
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Results of chemotherapy for gynecologic cancer patients in ambulatory care].
    Protasova AE; Orlova RV
    Vopr Onkol; 2011; 57(4):525-9. PubMed ID: 22191248
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Use of chemotherapy in oncogynecology].
    Nechaeva ID; Kotova DG
    Vopr Onkol; 1978; 24(3):106-15. PubMed ID: 347710
    [No Abstract]   [Full Text] [Related]  

  • 65. Adriamycin and bleomycin, alone and in combination, in gynecologic cancers.
    Barlow JJ; Piver MS; Chuang JT; Cortes EP; Onuma T; Holland JF
    Cancer; 1973 Oct; 32(4):735-43. PubMed ID: 4127428
    [No Abstract]   [Full Text] [Related]  

  • 66. Phase 1 trial of intraperitoneal AD-32 in gynecologic malignancies.
    Markman M; Homesley H; Norberts DA; Schink J; Abbas F; Miller A; Soper J; Teng N; Hammond N; Muggia F; Israel M; Sweatman T
    Gynecol Oncol; 1996 Apr; 61(1):90-3. PubMed ID: 8626124
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A discussion of the results of chemotherapy on gynecological cancer and the host's immune response.
    Trelford JD
    Proc Natl Cancer Conf; 1970; 6():365-85. PubMed ID: 5458106
    [No Abstract]   [Full Text] [Related]  

  • 68. Cyclosporin A reverses chemoresistance in patients with gynecologic malignancies.
    Sood AK; Sorosky JI; Squatrito RC; Skilling JS; Anderson B; Buller RE
    Neoplasia; 1999 Jun; 1(2):118-22. PubMed ID: 10933045
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Multi-drug chemotherapy for patients with peritonitis carcinomatosa associated with ascites].
    Hirono M; Yoshihara T; Hayashi Y; Suzuki M; Majima H
    Nihon Gan Chiryo Gakkai Shi; 1990 Mar; 25(3):672-8. PubMed ID: 2351859
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Systemic therapy for gynecologic cancer.
    Kavanagh JJ; Kudelka AP
    Curr Opin Oncol; 1993 Sep; 5(5):891-9. PubMed ID: 8105975
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Pharmacokinetics of consecutive low-dose cisplatin.
    Shimizu Y
    Oncol Rep; 1997; 4(3):591-3. PubMed ID: 21590104
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Rationale and clinical experience with epidermal growth factor receptor inhibitors in gynecologic malignancies.
    Vaidya AP; Parnes AD; Seiden MV
    Curr Treat Options Oncol; 2005 Mar; 6(2):103-14. PubMed ID: 15717992
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Combined radiation and chemotherapy in the treatment of gynecologic malignancies: preliminary results.
    Smaniotto D; Balducci M; Caspiani O; Ciarniello V; Summaria V; Montemaggi P
    Rays; 1993; 18(3):411-5. PubMed ID: 8284457
    [No Abstract]   [Full Text] [Related]  

  • 74. The role of ifosfamide in gynecologic cancer.
    Thigpen T; Lambuth BW; Vance RB
    Semin Oncol; 1992 Feb; 19(1 Suppl 1):30-4. PubMed ID: 1411619
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Chemotherapy of advanced gynecological cancer and its limitation--findings in compound and multidisciplinary treatment].
    Katashima S; Iwasaki M
    Nihon Gan Chiryo Gakkai Shi; 1983 Apr; 18(3):704-15. PubMed ID: 6619636
    [No Abstract]   [Full Text] [Related]  

  • 76. In vitro evaluation of cisplatin interaction with doxorubicin or 4-hydroperoxycyclophosphamide against human gynecologic cancer cell lines.
    Xu MJ; Alberts DS; Liu R; Leibovitz A; Liu Y
    Cancer Chemother Pharmacol; 1989; 25(2):89-94. PubMed ID: 2598404
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The clinical significance of calculated versus measured creatinine clearance in patients with gynecologic malignancy.
    Rao PS; Fiorica JV; Shah RP; Graham L; Roberts WS; Hoffman MS; Cavanagh D
    South Med J; 1996 Oct; 89(10):967-70. PubMed ID: 8865788
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Cytembena treatment of advanced gynaecological carcinomas.
    Dvorák O
    Neoplasma; 1971; 18(5):461-4. PubMed ID: 5119520
    [No Abstract]   [Full Text] [Related]  

  • 79. [A clinical phase III trial of MR-20 in gynecologic nephrotoxicity of cisplatin--a comparative study in MR-20-treated and control patients on cyclical intermittent cisplatin treatment].
    Ochiai K; Ikeda M; Kobayashi H; Nishimura H; Shibasaki T; Sakai O; Oh-hashi Y; Terashima Y
    Gan To Kagaku Ryoho; 1998 Apr; 25(5):713-22. PubMed ID: 9571969
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Systemic therapy for gynecologic cancer.
    Markman M
    Curr Opin Oncol; 1992 Oct; 4(5):939-45. PubMed ID: 1457510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.